Prime Medicine, Inc.
PRME
$3.49
$0.195.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.87% | -23.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.87% | -23.31% | |||
| Cost of Revenue | 1,267.00% | 12.68% | |||
| Gross Profit | -1,933.52% | -50.00% | |||
| SG&A Expenses | -14.55% | -1.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.30% | 1.20% | |||
| Operating Income | -1.12% | -1.88% | |||
| Income Before Tax | 3.82% | -1.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.82% | -1.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.82% | -1.35% | |||
| EBIT | -1.12% | -1.88% | |||
| EBITDA | -1.12% | -1.62% | |||
| EPS Basic | 22.60% | -2.67% | |||
| Normalized Basic EPS | 19.25% | -4.17% | |||
| EPS Diluted | 22.60% | -2.67% | |||
| Normalized Diluted EPS | 19.25% | -4.17% | |||
| Average Basic Shares Outstanding | 24.24% | -1.30% | |||
| Average Diluted Shares Outstanding | 24.24% | -1.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||